The National Institute of Allergy and Infectious Diseases, a division of the NIH, has awarded a $6.5 million grant to Dana-Farber Cancer Institute to help it develop a universal T cell-based vaccine against influenza A viruses. "Our ultimate goal is a vaccine that targets the conserved viral segments that cannot vary from one viral strain to another, thereby providing protection against all seasonal and pandemic flus," said Ellis Reinherz, the study's principal investigator.

Related Summaries